PLRX
PLIANT THERAPEUTICS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 11 ▲ Pliant Therapeutics reported fourth quarter 2025 financial results a…
- Apr 17 Pliant Therapeutics announced the retirement of three board members…
- May 11 ▼ Pliant Therapeutics reported Q1 2026 EPS of -$0.38, missing consensu…
- Aug 18 FDA: Pliant Therapeutics Receives FDA Fast Track Designation fo…
- Nov 12 ▼ Earnings: PLRX Q3 2026 Earnings: EPS $-0.39 (-3.3% vs est)
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q3 2026: 6 added (0 new), 10 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate −$0.388 → −$0.360 over 90 days. 2 up, 2 down in 30 days.
- Short sellersSTEADY
Short interest +5.3% to 4.88M shares. 16.2 days to cover, ≈7.9% of shares.
- TrendDOWNTREND
28% below its 50-day average. New closing low $0.6930 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| JANE STREET GROUP, LLC | ADD | $210.5K |
| MORGAN STANLEY | TRIM | $158.6K |
| JPMORGAN CHASE & CO | NEAR_EXIT | $116.2K |
| UBS Group AG | NEAR_EXIT | $109.8K |
| SIMPLEX TRADING, LLC | DOUBLED | $58.5K |
| Squarepoint Ops LLC | TRIM | $29.8K |
| Invesco Ltd. | NEAR_EXIT | $23.6K |
| FEDERATED HERMES, INC. | TRIM | $16.5K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Mar 2026Price is below the lowest target. Median implies +189%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Mar 13, 2026 | Canaccord Genuity MAINTAIN | Hold |
| Mar 12, 2026 | Piper Sandler MAINTAIN | Overweight |
| Nov 7, 2025 | RBC Capital MAINTAIN | Sector Perform |
| Oct 10, 2025 | JP Morgan DOWNGRADE | Underweight |
| Aug 8, 2025 | Piper Sandler MAINTAIN | Overweight |
| Mar 18, 2025 | HC Wainwright & Co. REITERATE | Neutral |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Raben David Chief Medical Officer Oct 1, 2026 | AWARD | 575,000 sh |
Iannone Robert Director Jul 9, 2026 | AWARD | 60,000 sh |
Borellini Flavia Director Jul 9, 2026 | AWARD | 60,000 sh |
Huh Hoyoung Director Jun 11, 2026 | AWARD | 70,000 sh |
Cline Darren S Director Jun 11, 2026 | AWARD | 70,000 sh |
Curnutte John T Director Jun 11, 2026 | AWARD | 70,000 sh |
Krognes Steve E. Director Jun 11, 2026 | AWARD | 70,000 sh |
MCCOURT Thomas A Director Jun 11, 2026 | AWARD | 70,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.36 | -$0.36–-$0.36 | +2.8% | $0.00 |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | -$1.44 | -$1.47–-$1.42 | -0.7% | $0.00 |
| Next FY | -$1.29 | -$1.47–-$0.94 | -0.8% | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
7 filings · 1 press release · 1 bullish · 1 bearish · 1 mixed · 4 neutral- NEUTRAL PRESS-RELEASENov 12, 2026
Pliant Therapeutics reported Q3 2026 net loss of $24.4M ($0.39 per share), slightly narrower than…
Monitor FORTIFY interim data expected in 2027 and further preclinical data on the RNAi delivery platform. The cash runway to mid-2028 provides a long development horizon, but the EPS miss and zero…
- BULLISH PRESS RELEASEAug 18, 2026
Pliant Therapeutics announced FDA Fast Track designation for PLN-101095, an oral dual integrin…
Fast Track designation is a modest positive for development timeline optionality but does not change the binary risk of Phase 1b data expected in 2027. Monitor FORTIFY enrollment updates and any…
- NEUTRAL 8-KMay 11, 2026
Pliant Therapeutics reported Q1 2026 results with a net loss of $20.0M ($0.32/share), narrower…
The EPS beat and cash runway extension are positive, but the stock's trajectory depends entirely on PLN-101095 clinical data. Interim FORTIFY data expected in 2027, no near-term catalysts. Monitor…
- BEARISH PRESS-RELEASEMay 11, 2026
Pliant Therapeutics reported Q1 2026 EPS of -$0.38, missing consensus of -$0.36 by 6.2%. Revenue…
The EPS miss reinforces the bearish sentiment for a pre-revenue biotech with no near-term catalysts until 2027 interim data. The $172.4M cash runway into H2 2028 provides a floor, but without a…
All PLRX filing & press-release reports (8)
- PRESS-RELEASE reportNov 12, 2026
- PRESS-RELEASE reportAug 18, 2026
- PRESS-RELEASE reportMay 11, 2026
- 8-K reportMay 11, 2026
- 8-K reportApr 17, 2026
- EFFECT reportApr 7, 2026
- 8-K reportMar 11, 2026
- 8-K reportMar 3, 2026